Viewing Study NCT07323056

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2026-03-26 @ 3:17 PM
Ignite Modification Date: 2026-03-30 @ 10:27 PM
Study NCT ID: NCT07323056
Status: RECRUITING
Last Update Posted: 2026-01-07
First Post: 2025-12-23
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None EGFR-mutant Non-small Cell Lung Cancer View
None Potentially Resectable View
Keywords:

Keywords

Keyword Brief Keyword Text View
None non-small cell lung cancer View
None EGFR-mutant View
None Sacituzumab Tirumotecan View
None Limertinib View